Article Detail

Home > Article Detail
  • P-ISSN 1225-0163
  • E-ISSN 2288-8985

Development of high performance liquid chromatography assay method of diosmin capsules

Analytical Science and Technology / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2016, v.29 no.6, pp.277-282
https://doi.org/10.5806/AST.2016.29.6.277









  • Downloaded
  • Viewed

Abstract

British Pharmacopoeia (BP 2013), the United States Pharmacopoeia (USP 39) and the Korean Pharmacopoeia (KP XI) contain monographs for the quality control of raw diosmin using high performance liquid chromatography (HPLC). However, official monographs detailing pharmaceutical formulations for diosmin are not available in foreign pharmacopoeias. In the KP XI, ultraviolet–visible (UV-Vis) spectroscopy—which is less specific than HPLC—is reported for the testing of diosmin capsules. In this study, we present an alternative HPLC assay for such testing that is more specific than UV-Vis methods. Method validation was performed to determine linearity, precision, accuracy, system suitability, and robustness. The linearity of calibration curves in the desired concentration range was high (r2>0.999), while the RSDs for intra- and inter-day precision were 0.15-0.29 % and 1.05-1.74%, respectively. Accuracies ranged from 101.2-103.2 %, while the retention time and peak area RSDs were 0.37 % and 0.06 %, respectively. Additionally, the plate number and asymmetry factor values for diosmin were 3591.293 and 1.35, respectively. Since the intermediate-precision and robustness of the assay were satisfactory, this method will be a valuable addition to the Korean Pharmacopoeia (KP XI).

keywords
Korean Pharmacopoeia(KP XI), diosmin capsule, assay, validation, high performance liquid chromatography


Reference

1

1. Ministry of Food and Drug Safety, No. A0-2015-2-006(2015.07.20), Republic of Korea.

2

2. Korea Pharmaceutical Information Center, http://www. health.kr/ingd_info/ingd_group/show_detail.asp?idx=632, Assessed 26 Jul 2016.

3

3. Ministry of Food and Drug Safety, The Korean Pharmacopoeia, 11th Edition, (2016), Republic of Korea.

4

4. Medicines & Healthcare Products Regulatory Agency, British Pharmacopoeia, 7th Edition, (2013), United Kingdom.

5

5. The United States Pharmacopeial Convention, The United States Pharmacopeia, USP 39 NF 34 (2016), United States.

6

6. M. K. Anwer, S. Jamil, M. J. Ansari, R. Al-Shdefat and M. S. Abdel-Kader, Int. J. Biol. Sci., 3, 41-46 (2014).

7

7. I. Saeidi, M. R. Hadjmohammadi, M. Peyrovi, M. Iranshahi, B. Barfi, A. B. Babaei and A. M. Dust, J. Pharm. Biomed. Anal, 56, 419-422 (2011).

8

8. M. A. Campanero, M. Escolar, G. Perez, E. Garcia-Quetglas, B. Sadaba and J. R. Azanza, J. Pharm. Biomed. Anal, 51, 875-881 (2010).

9

9. F. I. Kanaze, C. Gabrieli, E. Kokkalou, M. Georgarakis and I. Niopas, J. Pharm. Biomed. Anal, 33, 243-249(2003).

10

10. A. M. El-Shafae and M. M. El-Domiaty, J. Pharm. Biomed. Anal, 26, 539-545 (2001).

11

11. Ministry of Food and Drug Safety No. 2009-173 (2009. 12. 15), Republic of Korea.

12

12. Ministry of Food and Drug Safety, No. C0-2012-2-005(2012. 09. 19), Republic of Korea.

상단으로 이동

Analytical Science and Technology